Praglandia s.r.o.

Prague 47 trials 15 recruiting

47 Registered trials

15 Currently recruiting

Organisation

Praglandia s.r.o.

Location

Prague, Czechia

Identifier

ORG-100043161

Address

Ostrovskeho 253/3, Smichov, 150 00, Czechia

Departments

42001
Dermatology
Dermatovenerology
n/a
NA
Neurological Outpatient Clinic
Neurology
Praglandia s.r.o
Psychiatry

Clinical trials at this site (47)

Search interface

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ATTAIN-OSA) Ended

2024-515905-25-00 Overweight or Obesity 5 2025-01-29
A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended

2023-508096-36-00 atopic dermatitis 5 2024-10-30
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLV… Ended

2023-507456-69-00 Atopic Dermatitis 4 2024-04-25
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended

2023-506029-12-00 Migraine 5 2024-04-03
Efficacy and Safety of Methotrexate versus Placebo in Adults with Atopic Dermatitis Ended

2023-504443-13-00 moderate to severe atopic dermatitis 5 2024-01-29
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine… Ended

2022-501172-25-00 Chronic and Episodic Migraine 5 2024-01-17
Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended

2024-514404-13-00 Atopic Dermatitis 5 2020-10-01
A Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib Compared to Deucravacitinib in Participants With Moderate-… Ended

2024-512497-10-00 Moderate to Severe Plaque Psoriasis 5 2025-09-16
Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study of Efficacy and Safety of ESK-001 for Moderate to Severe Pl… Ended

2023-507193-40-00 Moderate to Severe Plaque Psoriasis 5 2025-01-16
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended

2024-511057-22-00 Major Depressive Disorder (MDD) with Moderate-to-severe 5 2024-12-04
Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermat… Ended

2023-508474-29-00 Dermatitis, Atopic 4 2024-10-30
A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in adult participants with severe … Ended

2024-511225-64-00 Alopecia areata 4 2024-09-18
A dose-finding trial with LU AG90222 in adults with migraine who have not been helped by prior preventative treatments. Ended

2023-508821-28-00 Migraine 4 2024-08-14
A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate-to-severe atop… Ended

2023-506558-20-00 Dermatitis atopic 5 2024-06-26
A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended

2023-506557-38-00 Dermatitis atopic 5 2024-05-16
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject… Ended

2023-505842-24-00 Moderate to Severe Plaque Psoriasis 5 2024-05-07
Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis Ended

2023-503522-40-01 Atopic Dermatitis 4 2024-04-10
A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinet… Ended

2023-505414-15-00 Dermatitis, Atopic 4 2024-04-10
Phase 2 study of SAR444656 in adult participants with moderate to severe atopic dermatitis. Ended

2023-504346-66-00 Dermatitis atopic 4 2024-02-14
A trial to evaluate the efficacy and safety of different doses of LEO 138559 in adults with moderate-to-severe atopic dermatitis. Ended

2022-500777-14-00 Atopic Dermatitis 4 2023-11-06
A Study of Daily Oral Orforglipron Compared with Insulin Glargine in Participants with Type 2 Diabetes and Obesity or Overweight at Increase… Ended

2022-502833-25-00 Obesity 5 2023-08-02
A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression. Ended

2023-508163-74-00 Major Depressive Disorder 5 2023-06-12
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended

2022-501538-44-00 Atopic Dermatitis 5 2023-04-25